The drugs for weight loss are becoming even more accessible with drug makers announcing a daily pill form of the active ingredient semaglutide rather than injecting the drugs on a weekly basis
Within this specific population, GLP-1 RAs exhibit major reductions in BW, BMI, WC, and SBP
The factors of visceral neuropathy, acute dysglycemia, dysbiosis, and intestinal bacterial overgrowth contribute to the gastrointestinal symptoms in patients with diabetes, making it necessary to consider multiple etiologic factors in the presence of gastrointestinal symptoms, and not exclusively attribute them to the use of antidiabetics
Pipeline of obesity pharmacotherapies GLP-1 receptor agonists GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig
[DOI] [PubMed] [Google Scholar] 71.Hayes MR, Skibicka KP, Grill HJ